Mupirocin: Price, Dosage & Where to Buy

Mupirocin is a topical antibacterial medicine, described as an RNA synthetase inhibitor, used to treat impetigo caused by susceptible bacteria. It is available as a cream and an ointment and requires a prescription in the United Kingdom. The skin ointment is intended for external skin treatment, not for use inside the nose, in the eyes or on other mucosal surfaces.

Mupirocin interferes with a bacterial enzyme involved in making proteins. Bacteria need these proteins to grow and carry out essential functions, so blocking their production helps stop susceptible bacteria from multiplying. This is why mupirocin is described as an RNA synthetase inhibitor antibacterial.

As a topical medicine, it acts at the treated skin site. Absorption into the body through intact skin is minimal.

Mupirocin ointment is indicated for the topical treatment of impetigo caused by susceptible Staphylococcus aureus or Streptococcus pyogenes bacteria. Susceptible means that the bacteria causing the infection are sensitive to the medicine's antibacterial action.

This indication relates to treatment on the skin. The skin ointment is not formulated for use inside the nose, in the eyes or on other mucosal surfaces; a separate nasal formulation is available.

The label lists cream strengths of 2 g/100 g and 20 mg/g, and an ointment strength of 20 mg/g. The label lists a small amount of 2% ointment on the affected area 3 times daily for up to 10 days, using a cotton swab or gauze pad. A gauze dressing may cover the treated area if desired.

The label calls for reassessment if there is no clinical response within 3 to 5 days. These are label facts rather than an individual treatment plan.

The ointment is for topical skin use only and is not intended for the nose, eyes or other mucosal surfaces. Concurrent use with other lotions, creams or ointments is not recommended.

The label specifies storage at 20-25°C (68-77°F). Keep the tube out of the sight and reach of children and follow the storage directions on the packaging to maintain quality.

A missed application can interrupt the intended treatment schedule. General pharmacy guidance is to resume the prescribed schedule when remembered, unless the next application is nearly due.

Avoid doubling an application to compensate. A pharmacist can clarify the schedule if there is uncertainty.

There are insufficient human data to establish whether mupirocin ointment carries a pregnancy-related risk. Absorption through intact skin is minimal. It is not known whether mupirocin enters human milk or affects a breastfed child or milk production, although exposure through breastfeeding is not expected because systemic absorption is minimal.

Any treated breast or nipple should be thoroughly washed before breastfeeding to minimise oral exposure. Discuss treatment during pregnancy or breastfeeding with a doctor or pharmacist.